

# Is low dose aspirin associated with a reduced risk of overall cancer among the French population (ASPIK)

**First published:** 03/07/2018

**Last updated:** 23/04/2024

Study

Ongoing

## Administrative details

### EU PAS number

EUPAS24699

### Study ID

24723

### DARWIN EU® study

No

### Study countries

☐ France

### Study status

Ongoing

## Research institutions and networks

# Institutions

## Centre de pharmaco-épidémiologie de l'APHP

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

## Contact details

### Study institution contact

Aya Ajrouche aya.ajrouche@inserm.fr

Study contact

[aya.ajrouche@inserm.fr](mailto:aya.ajrouche@inserm.fr)

### Primary lead investigator

Aya Ajrouche

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 03/02/2015

Actual: 03/02/2015

---

### Study start date

Planned: 02/01/2017

Actual: 02/01/2017

---

### **Date of final study report**

Planned: 01/10/2018

## Sources of funding

- Other

## More details on funding

Paris Diderot University, PHRC-k

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

**Study type:**

Non-interventional study

---

**Scope of the study:**

Effectiveness study (incl. comparative)

**Main study objective:**

This study aims to assess the effect of low dose aspirin use on overall cancer incidence among the French population.

## Study Design

**Non-interventional study design**

Cohort

## Study drug and medical condition

**Anatomical Therapeutic Chemical (ATC) code**

(B01AC06) acetylsalicylic acid

acetylsalicylic acid

---

**Medical condition to be studied**

Neoplasm malignant

## Population studied

**Age groups**

- Adults (46 to < 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
- 

### **Estimated number of subjects**

111000

## Study design details

### **Outcomes**

overall cancer (excluding non melanoma skin cancer), specific cancer sites

---

### **Data analysis plan**

We estimated the effect of low dose aspirin on cancer incidence by using a dynamic model to account for the competing risk of death in the presence of time-dependent exposure and risk factors.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

## **Data sources (types)**

Administrative healthcare records (e.g., claims)

## Use of a Common Data Model (CDM)

### **CDM mapping**

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No